Show simple item record

dc.contributor.authorCappello, F.
dc.contributor.authorMazzola, M.
dc.contributor.authorJurjus, A.
dc.date.accessioned2019-09-13T16:41:56Z
dc.date.available2019-09-13T16:41:56Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065907026&doi=10.3389%2ffphar.2019.00026&partnerID=40&md5=3e723126f3df1e259b9d841036ccb659
dc.identifier.urihttp://hdl.handle.net/10713/10658
dc.description.abstractInflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer. Copyright 2019 The Authors.en_US
dc.description.sponsorshipPart of this work was funded by the Italian National Operational Programme (PON) “Imprese e Competitività” 2014–2020 FESR, grant awarded by the Italian Ministry of Economic Development to the project titled “Gestione di un servizio integrato multicentrico di diagnostica e terapia personalizzata in oncologia” (Project code: F/090012/01-02/X36). AJLM and ECdeM were partially supported by IMET. FC was partially supported by IEMEST and UniPA.en_US
dc.description.urihttps://doi.org/10.3389/fphar.2019.00026en_US
dc.language.isoen-USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Pharmacology
dc.subjectChaperoning systemen_US
dc.subjectChaperonopathyen_US
dc.subjectChaperonotherapyen_US
dc.subjectHsp60en_US
dc.subjectImmune systemen_US
dc.subjectInflammatory bowel diseaseen_US
dc.subjectIntestinal wallen_US
dc.subjectMicrobiotaen_US
dc.titleHsp60 as a novel target in IBD management: A prospecten_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fphar.2019.00026


This item appears in the following Collection(s)

Show simple item record